Subscribe To
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek®

– CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participants with overweight or obesity without type 2 diabetes (T2D) – – CT-868 administered once-daily over 26 weeks showed robust glycemic control with ~70% of patients with T2D achieving HbA1c in the non-diabetes range – […] The post Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek® appear...
Read More
Content Topics
Carmot
Therapeutics
Highlights
Clinical
Data
From
Pipeline
Treatments
Obesity
Diabetes
Obesityweek
Forex
Posted: Oct 15 2023, 16:00
Author Name: forextv
Views: 082553